MindRank, a Hangzhou drug developer built around AI, says its lead candidate went from programme initiation to Phase III trials in roughly four and a half years on about $23mn of cumulative research spending.

Source: [TNW](https://thenextweb.com/news/mindrank-ai-drug-discovery-glp1-phase-three)

Sponsored